Insider Monkey
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20?
📊
AI Sentiment
Positive
7/10
- Home
- IBRX
IBRX
ImmunityBio Inc.
as of 11-28-2025 12:39pm EST
$2.32
+$0.19
+8.85%
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Chart Type:
Time Range:
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.3B | IPO Year: | N/A |
| Target Price: | $9.83 | AVG Volume (30 days): | 9.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.83 - $5.16 | Next Earning Date: | 11-04-2025 |
| Revenue: | $82,555,000 | Revenue Growth: | 1025.95% |
| Revenue Growth (this year): | 629.94% | Revenue Growth (next year): | 109.91% |
AI-Powered IBRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 72.48%
72.48%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest ImmunityBio Inc. News
IBRX Breaking Stock News: Dive into IBRX Ticker-Specific Updates for Smart Investing
Insider Monkey
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue
📈
AI Sentiment
Highly Positive
8/10
Compare IBRX vs Leading Stocks
See how IBRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IBRX ImmunityBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.